NanoDx has entered into a licensing arrangement with IBM Research to use the latter’s metal-oxide semi-conductive (CMOS) compatible nanoscale sensors to enhance and extend precise, quick testing for various indications. Covid-19, traumatic brain injury (TBI), sepsis, and stroke will all be tested by the firms. In addition, NanoDx is currently requesting an emergency use authorization from the US Food and Drug Administration for a rapid Covid-19 test that can provide results in two minutes at the point of service.
President and CEO of NanoDx Sharad Joshi said, “This global pandemic has further highlighted the need for a convenient, fast and accurate diagnostic so proper treatments can be delivered to patients as quickly as possible with the goal of shortening recovery times. As we move forward, our access to IBM’s technology in the in vitro diagnostics and biosensor fields will enable us to pursue developing a high throughput diagnostics platform at a significantly lower cost.”
This CMOS-compatible device, in particular, may be produced in an existing foundry, resulting in scalable and cost-effective hardware. In addition, NanoDx is now promoting the NanoDx System. This real-time, point-of-care diagnostics platform can identify and test biomarkers or analytes in under two minutes with a minimum fluid sample. Furthermore, the company has established an extensive intellectual property portfolio based on its nanosensor design and manufacturing processes, encompassing the whole field of in-vitro diagnostics.